Phase II study of disitamab vedotin (RC48) in combination with tislelizumab and bevacizumab in patients (Pts) with HER2 alterations locally advanced or metastatic NSCLC: Primary analysis results of ...

A phase I/Ib study of the aurora kinase A inhibitor alisertib in combination with osimertinib in advanced osimertinib-resistant EGFR-mutated lung cancer. A randomized phase II trial of 8 months of ...

New Exploratory Post-Hoc Analysis Examined the Relationship Between Reported Severe Maternal Morbidity (SMM) Outcomes and Cumulative Blood Loss Prior to JADA Insertion 1 JERSEY CITY, N.J.--(BUSINESS ...

SAN FRANCISCO--(BUSINESS WIRE)--PicnicHealth, a leading patient-centered healthcare evidence generation company, today announced the launch of a new study portal to facilitate faster, more accurate ...